QT Prolongation: May prolong QT interval. Monitor ECG in patients with a history of QT prolongation or who are taking medications which prolong the QT interval.
- Trade Name: Egaten (Novartis)
- Indications: Indicated for the treatment of fascioliasis in patients 6 years of age and older.
- Synonym: Egaten
- Class: Anthelmintic
- Half-life: 8 hours
- FDA Approval Date: 02/13/2019
- Clinically important, potentially hazardous interactions with:
ErdafitinibCYP2C19 substrates - Pregnancy: There are no available data on use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
